<DOC>
	<DOCNO>NCT00202917</DOCNO>
	<brief_summary>The purpose study study feasibility Toxicity allogeneic haploidentical hematopoietic cell transplantation CD3/CD19 deplete stem cell dose reduce conditioning .</brief_summary>
	<brief_title>Haploidentical Transplantation With CD3/CD19 Depleted Grafts Patients With Hematologic Malignancies</brief_title>
	<detailed_description>Transplantation CD3/CD19 deplete stem cell graft dose reduced conditioning treatment treatment refractory relapse hematologic malignancy precede allogeneic autologous hematopoietic cell transplantation .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Age &lt; 60 , &gt; 18 year Karnofsky &gt; 60 % High risk hematologic malignancy relapse precede auto/allo HCT patient : ALL AML PNH MDS ( RAEBt/secondary AML ) NHL ALL HD CML MM No HLAidentical MRD URD precede alloHCT Use haploidentical donor KIRMismatch choice &lt; 3 month precede HCT Active cerebral seizure &gt; 30 % blast BM ALL/AML/CMLBC Completely chemorefractory Preceding myocardial infarction Ejection fraction &lt; 30 % echocardiography Creatinine clearance &lt; 50 ml/min Respiratory insufficiency supplemental O2 DLCO &lt; 30 % Allergy murine antibody HIV infection Pregnancy Unable inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>haploidentical transplantation</keyword>
	<keyword>immunomagnetic cell sort</keyword>
	<keyword>allogeneic hematopoietic cell transplantation</keyword>
	<keyword>dose reduce conditioning</keyword>
</DOC>